Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance

Abstract

Background

All site-specific interactions between HIV type-1 (HIV-1) subtype, human leukocyte antigen (HLA)-associated immune selection and integrase inhibitor resistance are not completely understood. We examined naturally occurring polymorphisms in HIV-1-integrase sequences from 342 antiretroviral-naive individuals from the Western Australian HIV Cohort Study and the Swiss HIV Cohort Study.

Methods

Standard bulk sequencing and sequence-based typing were used to generate integrase sequences and high-resolution HLA genotypes, respectively. Viral residues were examined with respect to drug resistance mutations and CD8⁺ T-cell escape mutations.

Results

In both predominantly subtype B cohorts, 12 of 38 sites that mediate integrase inhibitor resistance mutations were absolutely conserved, and these included the primary resistance mutations. There were 18 codons with non-primary drug resistance-associated substitutions at rates of up to 58.8% and eight sites with alternative polymorphisms. Five viral residues were potentially subject to dual-drug and HLA-associated immune selection in which both selective pressures either drove the same amino acid substitution (codons 72, 157 and 163) or HLA alleles were associated with an alternative polymorphism that would alter the genetic barrier to resistance (codons 125 and 193). The common polymorphism T125A, which was characteristic of non-subtype B and was also associated with carriage of HLA-B*57/*5801, increased the mutational barrier to the resistance mutation T125K.

Conclusions

Primary integrase inhibitor resistance mutations were not detected in the absence of drug exposure in keeping with sites of high constraint. Viral polymorphisms caused by immune selection and/or associated with non-subtype B might alter the genetic barrier to some non-primary resistance-associated mutations.

References

Markowitz

, Morales-Ramirez

J.O.

, Nguyen

B.Y.

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

J Acquir Immune Defic Syndr 2006; 43: 509–515.

Cooper

D.A.

, Steigbigel

R.T.

, Gatell

J.M.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

N Engl J Med 2008; 359: 355–365.

Grinsztejn

, Nguyen

B.Y.

, Katlama

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial.

Lancet 2007; 369: 1261–1269.

Delelis

, Malet

, Na

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.

Nucleic Acids Res 2009; 37: 1193–1201.

Fransen

, Gupta

, Danovich

Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways. 17th International HIV Drug Resistance Workshop. 10–14 June 2008, Sitges, Spain. Abstract 7.

Shimura

, Kodama

, Sakagami

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).

J Virol 2008; 82: 764–774.

Johnson

V.A.

, Brun-Vezinet

, Clotet

Update of the drug resistance mutations in HIV-1.

Top HIV Med 2008; 16: 138–145.

Lataillade

, Chiarella

, Kozal

M.J.

Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.

Antivir Ther 2007; 12: 563–570.

, Anderson

, Ferns

Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

AIDS Res Hum Retroviruses 2008; 24: 1003–1007.

10.

Myers

R.E.

, Pillay

Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.

J Virol 2008; 82: 9228–9235.

11.

Dicker

I.B.

, Terry

, Lin

Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.

J Biol Chem 2008; 283: 23599–23609.

12.

Lee

D.J.

, Robinson

W.E.

Jr. , Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother 2006; 50: 134–142.

13.

Nakahara

, Wakasa-Morimoto

, Kobayashi

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.

Antiviral Res 2009; 81: 141–146.

14.

Kobayashi

, Nakahara

, Seki

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.

Antiviral Res 2008; 80: 213–222.

15.

Goulder

P.J.

, Watkins

D.I.

Impact of MHC class I diversity on immune control of immunodeficiency virus replication.

Nat Rev Immunol 2008; 8: 619–630.

16.

Brumme

Z.L.

, Tao

, Szeto

Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection.

AIDS 2008; 22: 1277–1286.

17.

John

, Heckerman

, Park

Genome-wide HLA-associated selection in HIV-1 and protein-specific correlations with viral load: an ACTG5142 study. 15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract 312.

18.

Rousseau

C.M.

, Daniels

M.G.

, Carlson

J.M.

HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load.

J Virol 2008; 82: 6434–6446.

19.

John

, Moore

C.B.

, James

I.R.

, Mallal

S.A.

Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.

Antivir Ther 2005; 10: 551–555.

20.

Karlsson

A.C.

, Deeks

S.G.

, Barbour

J.D.

Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.

J Virol 2003; 77: 6743–6752.

21.

Moore

C.B.

, John

, James

I.R.

, Christiansen

F.T.

, Witt

C.S.

, Mallal

S.A.

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.

Science 2002; 296: 1439–1443.

22.

Mueller

S.M.

, Schaetz

, Eismann

Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.

J Virol 2007; 81: 2887–2898.

23.

Gaudieri

, Rauch

, Pfafferott

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new anti-viral therapy.

Hepatology 2009; 49: 1069–1082.

24.

Adamson

C.S.

, Ablan

S.D.

, Boeras

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat).

J Virol 2006; 80: 10957–10971.

25.

Mallal

S.A.

The Western Australian HIV Cohort Study, Perth, Australia.

J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17 Suppl 1: S23–S27.

26.

Ledergerber

, von Overbeck

, Egger

, Luthy

The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics.

Soz Praventivmed 1994; 39: 387–394.

27.

Swiss HIV Cohort Study. (Accessed 05 December 2008.) Available from www.shcs.ch.

28.

Witt

C.S.

, Price

, Kaur

Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe.

Tissue Antigens 2002; 60: 474–480.

29.

Oelrichs

R.B.

, Lawson

V.A.

, Coates

K.M.

, Chatfield

, Deacon

N.J.

, McPhee

D.A.

Rapid full-length genomic sequencing of two cytopathically heterogeneous Australian primary HIV-1 isolates.

J Biomed Sci 2000; 7: 128–135.

30.

Chopra

, Degenaar

, Rushton

High throughput sequencing of full length HIV-1 genomes. 4th International AIDS Conference on HIV Pathogenesis, Treatment and Prevention. 22–25 July 2007, Sydney, Australia. Abstract WEPEA 049.

31.

National Center for Biotechnology Information. Genotyping tool. (Accessed September 2008.) Available from http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi.

32.

Tamura

, Dudley

, Nei

, Kumar

MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0.

Mol Biol Evol 2007; 24: 1596–1599.

33.

Shannon

C.E.

The mathematical theory of communication. 1963.

MD Comput 1997; 14: 306–317.

34.

Carlson

, Kadie

, Mallal

, Heckerman

Leveraging hierarchical population structure in discrete association studies.

PLoS ONE 2007; 2: e591.

35.

EMBL-EBI. Human leukocyte antigen allele ethnicity tool. (Updated October 2008. Accessed November 2008.) Available from http://www.ebi.ac.uk/imgt/hla/ethnicity.html.

36.

Heckerman

, Kadie

, Listgarten

Leveraging information across HLA alleles/supertypes improves epitope prediction.

J Comput Biol 2007; 14: 736–746.

37.

Hossain

M.S.

, Tomiyama

, Inagawa

, Ida

, Oka

, Takiguchi

Identification and characterization of HLA-A*3303-restricted, HIV type 1 Pol- and Gag-derived cytotoxic T cell epitopes.

AIDS Res Hum Retroviruses 2003; 19: 503–510.

38.

Organization. The Blosum clustered scoring matrix. (Updated 26 August 1997. Accessed November 2008.) Available from ftp://ftp.ncbi.nih.gov/blast/matrices/BLOSUM62.

39.

Allen

T.M.

, Altfeld

, Geer

S.C.

Selective escape from CD8⁺ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution.

J Virol 2005; 79: 13239–13249.

40.

Feeney

M.E.

, Tang

, Pfafferott

HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response.

J Immunol 2005; 174: 7524–7530.

41.

Rhee

S.Y.

, Liu

T.F.

, Kiuchi

Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.

Retrovirology 2008; 5: 74.

42.

Malet

, Soulie

, Tchertanov

Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases.

J Med Virol 2008; 80: 754–761.

43.

Carrington

, O'Brien

S.J.

The influence of HLA genotype on AIDS.

Annu Rev Med 2003; 54: 535–551.

44.

Martinez-Picado

, Prado

J.G.

, Fry

E.E.

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.

J Virol 2006; 80: 3617–3623.

45.

Brenner

B.G.

, Oliveira

, Doualla-Bell

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

AIDS 2006; 20: F9–F13.

46.

Grossman

, Paxinos

E.E.

, Averbuch

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.

Antimicrob Agents Chemother 2004; 48: 2159–2165.

47.

Kantor

, Katzenstein

D.A.

, Efron

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

PLoS Med 2005; 2: e112.

48.

Danovich

, Ke

, Wan

Raltegravir has similar in vitro antiviral potency, clinical efficacy, and resistance patterns in B subtype and non-B subtype HIV-1. XVII International AIDS Conference. 3–8 August 2008, Mexico City, Mexico. Abstract TUAA 0302.

49.

Mason

R.D.

, Bowmer

M.I.

, Howley

C.M.

, Gallant

, Myers

J.C.

, Grant

M.D.

Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes.

J Immunol 2004; 172: 7212–7219.

50.

Schmitt

, Harrer

, Goldwich

Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes.

AIDS 2000; 14: 653–658.

51.

Eron

J.A.J.

, Zajdenverg

Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 70aLB.